Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Generic brimonidine availability yields lower cost to patient
Generic brimonidine tartrate (Bausch & Lomb), which is formulated differently from the trade formulation (Alphagan P, Allergan), became widely available during the second half of 2003 and seems to be gaining acceptance with ophthalmologists in many cases because of the drug's lower cost.
Related Videos
Related Content
